%0 Journal Article
%T Individualized Dose-Response to Statins Associated with Cardiovascular Disease Outcomes.
%A Aggarwal SK
%A Jiang L
%A Liu G
%A Grabowska ME
%A Ong HH
%A Wilke RA
%A Feng Q
%A Wei WQ
%J JACC Adv
%V 3
%N 4
%D 2024 Apr
%M 38737008
暂无%R 10.1016/j.jacadv.2024.100894
%X UNASSIGNED: Statins reduce low-density lipoprotein cholesterol (LDL-C) and are efficacious in the prevention of atherosclerotic cardiovascular disease (ASCVD). Dose-response to statins varies among patients and can be modeled using three distinct pharmacological properties: (1) E0 (baseline LDL-C), (2) ED50 (potency: median dose achieving 50% reduction in LDL-C); and (3) Emax (efficacy: maximum LDL-C reduction). However, individualized dose-response and its association with ASCVD events remains unknown.
UNASSIGNED: We analyze the relationship between ED50 and Emax with real-world cardiovascular disease outcomes.
UNASSIGNED: We leveraged de-identified electronic health record data to identify individuals exposed to multiple doses of the three most commonly prescribed statins (atorvastatin, simvastatin, or rosuvastatin) within the context of their longitudinal healthcare. We derived ED50 and Emax to quantify the relationship with a composite outcome of ASCVD events and all-cause mortality.
UNASSIGNED: We estimated ED50 and Emax for 3,033 unique individuals (atorvastatin: 1,632, simvastatin: 1,089, and rosuvastatin: 312) using a nonlinear, mixed effects dose-response model. Time-to-event analyses revealed that ED50 and Emax are independently associated with the primary endpoint. Hazard ratios were 0.85 (p < 0.01), 0.83 (p < 0.01), and 0.87 (p = 0.10) for ED50 and 1.13 (p < 0.001), 1.06 (p < 0.001), and 1.15 (p = 0.009) for Emax in the atorvastatin, simvastatin, and rosuvastatin cohorts, respectively.
UNASSIGNED: The class-wide association of ED50 and Emax with clinical outcomes indicates that these measures influence the risk for ASCVD events in patients on statins.